Pyxis Oncology is trading 5.68% up at $1.86, with no identified company-specific announcement explaining the October 20 move.
- The latest investor-relations release located is dated October 2.
- Biotech-sector strength may provide context, but the supplied sector reading describes the prior session, not a confirmed October 20 catalyst.
- A Wells Fargo Buy reiteration was reported October 18, but available evidence does not establish it as the cause of today’s gain.